News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL May 31, 2022
General News Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 EN NL May 25, 2022
General News Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 EN May 24, 2022
General News Regulated Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) EN NL May 9, 2022
General News Regulated Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 EN NL May 6, 2022
General News Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN May 3, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA EN NL April 29, 2022
General News Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN April 11, 2022
General News Regulated Oxurion Announces Extraordinary and Annual Shareholders’ Meetings EN NL April 1, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA EN NL March 30, 2022
News Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG EN NL March 17, 2022
General News Regulated Oxurion succesfully raises EUR >10 MILLION from leading US and European healthcare investors in a private equity placement EN NL March 3, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL February 22, 2022
General News Regulated Oxurion NV announces 2021 Full Year Results and 2022 Outlook EN NL February 22, 2022
General News Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN February 14, 2022
General News Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference EN February 11, 2022
